

Innovation Driven Outcomes Focused

May 2023

INHIBR_x



Presentation disclaimer

This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements regarding Inhibrx, Inc.’s (the “Company”) business strategy, the Company’s plans to develop and commercialize its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to clinical trials and regulatory filings and approvals, manufacturing matters, strength of intellectual property protection, and the size and growth potential of the markets for the Company’s product candidates, and any implication that pre-clinical data or preliminary or topline results will be representative of the results of later trials. This presentation also contains certain projections and estimates regarding the Company’s future financial performance, namely potential future revenue for certain of the Company’s product candidates. This information also constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of any future results. The assumptions and estimates underlying this estimated financial information are inherently uncertain and subject to a wide variety of significant business, economic competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. These potential financial information and other forward-looking statements involve substantial known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Additional information regarding the Company’s risks and uncertainties are described from time to time in the “Risk Factors” section of our Securities and Exchange Commission filings, including those described in our Annual Report on Form 10-K as well as our Quarterly Reports on Form 10-Q, and supplemented from time to time by our Current Reports on Form 8-K.

The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements the Company makes. The forward-looking statements in this presentation represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this presentation.

The investigational product candidates discussed in this presentation have not been approved or licensed by the U.S. Food and Drug Administration or by any other regulatory authority, and they are not commercially available in any market. This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the Company’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Inhibrx, the Inhibrx logo and ContraMAB are registered trademarks of Inhibrx, Inc. All third-party trademarks used herein are registered trademarks of their respective owners.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

Why Inhibrx Should Be Front and Center on Your Radar



Four Biologic Programs in the Clinic

All are demonstrating clinical activity with multi-billion-dollar potential peak sales. Two registration-enabling programs are underway in 1H 2023.



Active Discovery Process

Six programs are expected to enter the clinic over the next three years.



Opportunities to Both Partner Assets and Commercialize In-house

We believe our assets appeal to major pharmaceutical companies as licensing targets. We are building the infrastructure to internally execute on small commercial footprint opportunities.



Our Interests are Aligned With Our Investors

Credible base of major holders and ~30% internally owned. Potential to become financially self-sustaining within 18 months with no debt and possible return of capital to investors through share buy-backs and/or special dividends.

Innovative Approach to Biologic Therapeutic Discovery & Development

Settlers, Not Pioneers



- + Best targets are known and already explored, but what is not known is how to drug them properly
- + We learn through prior clinical failures and therapeutic liabilities
- + We only move programs into the clinic that are first or best-in-class with a clear path to point of concept



Broad Internal Expertise



- + The modular nature of our platforms and technologies combined with our protein engineering expertise allow for rapid exploration of therapeutic approaches
- + Teams with deep biologics drug development expertise across translational sciences, clinical, technical operations, manufacturing and commercial



Success Where Others Have Failed



- + First company to optimize and develop recombinant AAT
- + First company to overcome DR5 agonism toxicity challenges and advance into registration-enabling study
- + First company to find a therapeutic window for 4-1BB

Our Clinical Therapeutic Candidates

	Preclinical	Phase 1	Registration-enabling	
INBRX-101- AATD <i>Our Recombinant Alpha-1-Anti-trypsin Fc-Fusion Protein (AAT-Fc)</i>				+ No innovation for 30+ years and multiple recombinant AAT failures + Favorable safety and tolerability profile w/potential to achieve normal AAT levels with monthly dosing + Initiation of registration-enabling trial in April 2023; Potential path to launch in 2026; \$3B+ peak sales potential
INBRX-109 <i>Our Tetravalent DR5 Agonist</i>				+ Prior DR5 agonist efforts failed due to limited activity or hepatotoxicity + At-risk population for severe liver toxicity now identified and screening criteria protocol updated + Data from registration-enabling trial expected in 2H 2024 with possible path to approval in chondrosarcoma in 2025
INBRX-105 <i>Our Tetravalent PD-L1 targeted 4-1BB Agonist</i>				+ We believe we are the first to find a therapeutic window for 4-1BB agonism + Based on incoming clinical data, we are growing more confident this could be a blockbuster drug, potentially as a single agent + Data update in 2H 2023 with potential for registration studies to start early next year
INBRX-106 <i>Our Hexavalent OX40 Agonist</i>				+ OX40 is a validated target but no one has been able to build a viable multivalent antibody + Clinical data looks promising with durable single agent activity + Substantial data update in 1H 2024 with registration studies as early as 2H 2024

Our Upcoming Therapeutic Candidates

All potential best-in-class with differentiated profiles

INBRX-101- GvHD


Our Recombinant Alpha-1-Anti-trypsin Fc-Fusion Protein (AAT-Fc)



- + De-risked opportunity with promising published clinical data with pdAAT
- + Potential to reach >\$3B peak sales in Acute GvHD and Chronic GvHD
- + Clinical trial(s) to initiate 1H 2024

INBRX-121

Our NK cell targeted IL-2



- + NKp46 targeting with engineered IL-2 drives selective NK cell expansion and enhancement of cytotoxicity capacity
- + Phase 1 trial could initiate in Q4 2023

Other Programs on the Horizon

- + FcRN Antagonist
- + Radiopharmaceuticals
- + T-cell Engagers - ContraMAB® Platform
- + $\gamma\delta$ T-cell Targeted Cisleukin™ Molecule

Partnerships with Industry Leaders

PARTNER	FOCUS
 Bristol Myers Squibb™	CD47 checkpoint inhibitor
 Chiesi People and ideas for innovation in healthcare	Option to Ex-North America rights to INBRX-101 AATD
 2seventybio™	Use of INBX sdAb platform for certain cell therapy products for up to 13 programs
 MERCK	Merck-supplied Keytruda® for INBRX-106 Phase 1 combo trial
 ARROWMARK PARTNERS	Joint venture with ArrowMark affiliate, Phylaxis Bioscience, LLC: license of IP and know-how to develop certain compounds
 Elpiscience	Greater China rights to INBRX-105 and INBRX-106

Key financial highlights



\$234M

Cash and cash equivalents

> 30%

Internal ownership

43.6M

Common stock outstanding

50.8M

Fully diluted outstanding


~145

Employees

* As of 3/31/2023

INHIBRX

Near Term Expected Clinical Milestones



INBRX-101

Recombinant Alpha-1
Antitrypsin Fc-fusion Protein


INHIBR_X

INBRX-101

Alpha-1 Antitrypsin
Deficiency (AATD)

INHIBR_X

Functional AAT Levels in Healthy Individuals vs. AATD Patients



Disease history

- + Alpha-1 antitrypsin deficiency (AATD) is an inherited orphan respiratory disease characterized by deficient levels of alpha-1 antitrypsin (AAT)
- + This causes loss of lung function and decreased life expectancy
- + A small percentage of patients also develop liver disease


Study results

- + Functional AAT levels from 65 MM genotype healthy volunteers ranged from 21 to 54 micromolar (μM), with a mean of 36 μM.
- + Baseline levels of functional AAT for 30 Phase 1 patients prior to dosing of INBRX-101 ranged from 2 to 18 μM, with a median of 4.7 for ZZ genotype patients.

- Box plots show the minimum, lower quartile, median, upper quartile and maximum
- The shaded region represents the 5th-95th percentiles of the normal range of functional AAT in healthy MM genotype adults
- AAT variant determination was conducted by the Mayo Clinic Laboratories using an LC-MS/MS method (A1ALC)
- The Phase 1 baseline data represents the functional AAT levels measured in patients at the beginning of the study prior to dosing INBRX-101

Current Standard of Care Does Not Maintain Normal AAT Levels

INBRX-101



36 μM mean of functional AAT normal range*

11 μM historical putative threshold

+ INBRX-101, dosed **every four weeks** at 120 mg/kg, is predicted to maintain patients above the lower threshold of the normal range and achieve an average level (C_{avg}) of functional AAT that approximates that of healthy MM genotype adults.*

+ The current standard of care, plasma-derived AAT (pdAAT)**, dosed **once weekly** at 60 mg/kg, achieves C_{avg} of functional AAT of 17.8 μM over the weekly dosing interval as calculated from steady-state area under the curve (AUC) values***. Due to its short half-life, patients require weekly infusions to achieve target levels, but levels typically fall below the normal range within 1-2 days of infusion.

*Source~ Normal range calculated based on Inhibrx ANEC assay results from 65 healthy MM genotype adults

**Current pdAAT therapies include: Aralast, Glassia, Prolastin-C & Zemaira


***Source~ reported in Stocks et al. BMC Clinical Pharmacology 2010, 10:13

INHIBRX

Potential Advantages of Recombinant AAT Fc-fusion Protein




Potential to extend
the dosing interval
from weekly to monthly



Has demonstrated potential to
maintain patients in normal
functional AAT range



Recombinant manufacturing
provides abundant supply
with no pathogen risk



INBRX-101 - Topline Results from Phase 1, Part 2

PART 2



**Multiple ascending
dose escalation (MAD)**



Complete



N=18



N=6



40 mg/kg



N=6



80 mg/kg*



N=6




120 mg/kg*

* bronchoalveolar lavage

- + Favorable safety and tolerability profile with only mild and a few moderate AEs that were transient and fully reversible with minimal or no symptomatic care
- + Dose related increases in maximal and total exposure occurred across entirety of SAD and MAD ranges of 10-120 mg/kg
- + Revealed potential to achieve and maintain normal functional AAT levels with monthly dosing

INBRX-101 topline results – 3rd dose of 40, 80 or 120 mg/kg (Q3W)



↑ Indicates timing after third dose

* Baseline values shown at Day 0

- + Significant accumulation observed following each MAD dose in-line with the prolonged terminal elimination half-life of INBRX-101
- + MAD cohorts demonstrate observed C_{avg} of functional AAT of 37.6 µM and 45.4 µM over the 21-day dosing interval following the third 80 mg/kg and 120 mg/kg doses, respectively
- + Functional AAT levels at Day 70 (28 days following the 3rd dose), on average, were within the normal range for the 120 mg/kg dose level

INBRX-101

INHIBRX

INBRX-101 is Present in the Lung in Every Patient Sampled Following IV Dosing

Bronchoalveolar lavage fluid (BALF) sample collection and analysis


- + BALF samples were collected from 3 lobes of the lung for each patient in the 80 (N = 5)¹ and 120 (N = 6) mg/kg MAD cohorts prior to dosing and two weeks after completion of multiple dosing
- + INBRX-101 concentrations were measured using a proprietary validated mass spectrometry assay specific to INBRX-101

BALF assessment results

- + At baseline, BALF samples from subjects that rolled over from the Part 1 SAD² had measurable INBRX-101 while drug was undetectable in INBRX-101 naïve patients (data not shown)
- + Post-dose, INBRX-101 was present in each lung lobe of every patient for which a bronchoscopy was performed
- + The Phase 1 study data provide emerging evidence of a dose-dependent increase in INBRX-101 lung exposure

¹ One 80 mg/kg patient did not have a post-dose sample collected

² In rollover patients, baseline collection was at least 84 days after the SAD



- ✓ Each point represents the average INBRX-101 concentration measured across three lobes in an individual subject
- ✓ Horizontal lines are the median values for each dose level

INBRX-101 AATD Registration-enabling Trial

Main Eligibility Criteria

- + Adult patients aged 18-80 with AATD and evidence of emphysema
- + AAT antigenic serum concentration <11 μ M
- + Nonsmoker or former smoker
- + 5-week washout for those on augmentation therapy
- + Randomization stratified by baseline antigenic AAT & FEV1 (% predicted)



Initiated

- + Randomized, controlled, double-blind
- + Head-to-head superiority study: INBRX-101 vs. pdAAT
- + 32-week treatment period
- + ~40 US, AUS, NZ sites



N=36



INBRX-101 at 120 mg/kg Q3W & placebo on non-dosing weeks



N=36



INBRX-101 at 120 mg/kg Q4W & placebo on non-dosing weeks



N=18



pdAAT at approved dose of 60 mg/kg QW

Primary Endpoint: Mean change in avg fAAT concentration as measured by anti-neutrophil elastase capacity (ANEC) from baseline to average serum trough fAAT concentration at steady state ($C_{trough,ss}$)

Key Secondary Endpoints: INBRX-101 vs pdAAT: mean change in fAAT concentration from baseline to fAAT avg concentration at steady state ($C_{avg,ss}$), and % of days with fAAT above the lower limit of the normal range during steady-state dosing; Bronchoscopy sub-study of ~ 30 patients to run at designated sites

Study INBRX101-01-202: ElevAATe-OLE (Open Label Extension)

- + Open label, long-term safety and tolerability study
- + Combination of naïve and rollover patients from ElevAATe
- + Minimum treatment duration of 3 years
- + ~40 US, AUS, NZ sites



N=130



INBRX-101 120 mg/kg Q3W




INBRX-101

INHIBR

INBRX-101 has the Potential to Achieve ~\$3B in Annual U.S. Revenue with Expected Rapid Uptake in Patients with Severe AATD

INBRX-101 top line projected U.S. sales & key assumptions



Key assumptions

- + “Severe (ZZ/SZ)” AATD patients (same as pdAATs today)
- + 7% CAGR throughout forecast period (conservative estimate given CAGR of ~17% from 2016 to 2020)
- + ~75% peak market share
- + 3-year time to peak share
- + Price parity with current pdAATs* & 2% annual price growth
- + Little to no generic erosion due to high barriers to entry

INBRX-101

INHIBRX

INBRX-101 has the Potential to Shift the Treatment Paradigm, Expanding Augmentation Therapy to a Broad Group of AATD Patients in the U.S.

INBRX-101

	TODAY	FUTURE
	PI*ZZ or PI*SZ	PI*ZZ or PI*SZ
U.S. prevalence	~100K	~100K (same as today)
Treatment rate	~8-10%	~40% (driven by increased diagnosis rates)
Total treated U.S. patients	~8K	~40K
Market revenue potential	~\$1 Billion	~\$4 Billion

Key Takeaways for AATD Market:

- + pdAATs only utilized for severe AATD patients and market is still worth ~\$1B today despite only ~8-10% treatment rate
- + PI*ZZ & PI*SZ AATD market is growing at ~17% annually and projected to grow to \$4B due to increased diagnosis
- + Upside market potential from earlier intervention of augmentation therapy, which can help to prevent lung decline
- + Commercial viability and expansion of augmentation therapy use requires abundant supply only available via INBRX-101

“The results of the RAPID trial stress the importance of early intervention. Patients who started augmentation late were unable to regain lung tissue lost during placebo treatment and did not ‘catch up’ to patients who started augmentation early.” – U.S. KOL

INBRX-101

Graft versus Host Disease
(GvHD)

INHIBR_X

Strong Clinical Data and Established Guidelines Exist for AAT Therapy in Acute GVHD

Existing clinical data for Jakafi: current standard of care

2L (steroid resistant) acute GVHD (aGVHD)

	Ruxolitinib, Incyte ⁴ (n=49)
Efficacy	
ORR (%) at day 28 (per CIBMTR)	28/49 (57%)
CR (%) at day 28	15/49 (31%)
OS	51% at 6 months
Safety (n=71)	
Grade 3+ AEs	97.2%
Most Frequent AEs	+ Anemia: 64% + Thrombocytopenia 62% + Neutropenia 48%
Incidence of Infection	80%
Dosing	• 5-10 mg twice daily

Existing clinical data for plasma-derived AAT therapies 2L (steroid resistant) aGVHD

	Fred Hutch/Baxalta ¹ Ph1/2 (n=12)	U of Michigan/CSL ² AAT +/- Prednisone Ph2 (n=40)
Efficacy		
ORR (%) at day 28 (per CIBMTR)	8/12 (67%)	26/40 (65%)
CR (%) at day 28	4/12 (33%)	14/40 (35%)
OS	6/12 alive	45% at 6 months
Grade 3+ AEs	0%	0%
Safety		
Most Frequent AEs	"No clinical apparent toxicity in any patient" 2 d/c due to lack of efficacy	"well tolerated with no infusion reactions or drug-related grade 3 to 4 toxicity"
Incidence of Infection	0	13/40 (32.5%) Through 30 days
Dosing	90 mg/kg loading dose followed by either 30 or 60 mg/kg every other day	60mg/kg per day every four days

Current guidelines for aGVHD⁵

National comprehensive cancer network (nccn)	Ruxolitinib (category 1)	Alemtuzumab	Alpha-1 antitrypsin	Anti-thymocyte globulin	Basiliximab	Calcineurin inhibitors	Etanercept
European society for blood and marrow transplantation (ebmt)	Alemtuzumab	Alpha-1 antitrypsin	Basiliximab	Cellular therapies	Daclizumab	Extracorporeal photopheresis	Faecal microbiota transplantation

INBRX-101

Two active Phase 2/3 studies sponsored by CSL Behring

- + The safety and efficacy of alpha-1 antitrypsin (AAT) for the prevention of graft-versus-host disease (GVHD) in patients receiving hematopoietic cell transplant (MODULAATE) (NCT03805789)³
- + Treatment of GVHD in hematopoietic stem cell transplant (HSCT) recipients using AAT plus corticosteroids (CS) compared with corticosteroids alone (NCT04167514)³

Sources:

¹ Response of Steroid-Refractory Acute GvHD to a1-Antitrypsin, Marcondes et al, 2016. <http://dx.doi.org/10.1016/j.bbmt.2016.05.011>

² a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease, Magenau et al, 2018. <http://ashpublications.org/blood/article-pdf/131/12/1372/1405639/blood815746.pdf>

³ <https://clinicaltrials.gov/>

⁴ <https://www.jakafi.com/pdf/prescribing-information.pdf>, <https://ashpublications.org/blood/article/135/20/1739/452638/Ruxolitinib-for-the-treatment-of-steroid>

⁵ Listed in alphabetical order and not comprehensive of all consensus recommendations for steroid-refractory GVHD.

INBRX-101 has the Potential for Fast Entry into Acute GVHD, Expanding to Prophylaxis, Achieving >\$1bn in the US Market


INBRX-101 acute & prophylaxis GvHD top line projected US sales & key assumptions

Potential advantages over pdAAT

- + Potential for sustainable dosing schedule
- + Potential for transformational efficacy at higher dose
- + Ability to price in-line with current standard of care while pdAAT would be more expensive due to COGS and the high dose required
- + Near elimination of pathogenic risk for immunocompromised patients

Potential advantages over standard of care

- + Expected superior safety benefits with potential for greater efficacy



*Launch of prophylaxis indication

Key assumptions:

- + TPP: Superior safety, efficacious in prophylaxis, same efficacy in acute
- + Patients: Allogeneic stem cell transplants (2.3% annual growth), Acute 2L+, high risk prophylaxis (30%)
- + Share: Acute 2L: 50%, 3L: 70%, Prophylaxis: 21%
- + Time to peak: 2 years for acute and prophylaxis (5 years peak total)
- + Price: In-line with approved GvHD branded agents, 2.5% annual growth

Upside potential:

- + Potential for transformational efficacy at high dose
- + Safety profile could enable broad combinability across current and future therapies, including 1L

INBRX-101 GvHD Expansion Opportunities

U.S. chronic GvHD – progression beyond steroids

US Prevalence (2022)	~16,000 ⁶	 ~\$2bn 2030 US Market Opportunity
Extensive disease requiring therapy (50%) ⁴	8,000	
Progression beyond Steroids (71%) ⁴	5,700	

- + Less competitive future market landscape
- + Longer therapy duration requires reduced toxicity and steroid-sparing agents
- + Favorable safety profile enables opportunity for combining with standards of care
- + Long half-life enables sustainable long-term utilization of 101 relative to pdAAT therapies

Prophylaxis, acute, & chronic GvHD – EU / Japan

Europe & Japan Allogeneic Transplants	21,000 ^{2, 3}	 >\$3bn 2030 EU & JP Market Opportunity ⁵
--	------------------------	---

- + Favorable pricing and reimbursement as compared to typical European/Japanese standards due to high mortality and significant unmet medical need
- + There were 9,400¹ allogeneic transplants in the U.S. market; ex-US transplant market represents a large global opportunity

Sources:

¹ 2019 figures from HRSA Blood Stem Cell (<https://bloodstemcell.hrsa.gov/data>)

² 2017 figures for 40 European countries and 10 related countries: <https://www.nature.com/articles/s41409-019-0465-9>

³ 2020 figures from JDCHCT https://drive.google.com/file/d/16Vv8k1aHTMcOKbmOHGiUmEk4rFGwgBEy/view?usp=drive_web

⁴ Qualitative research, third-party analysis and current therapy pricing research, HRSA Blood Stem Cell (<https://bloodstemcell.hrsa.gov/data>).

⁵ Assumes pricing corridor 50% smaller than the US

⁶ Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis, Bachier, et. al., 2021

INBRX-109

Tetravalent DR5 Agonist

INHIBR_X

A Next Generation DR5 Agonist with an Optimized Balance of Efficacy and Safety

INBRX-109

- + **Death Receptor 5 (DR5/TRAIL-R2)** has been a target of interest in oncology due to the differential sensitivity of cancerous cells over healthy cells to TRAIL-mediated killing.¹⁻⁵ DR5 is a key receptor for TRAIL-induced apoptosis of unwanted, damaged, virally infected and transformed cells⁶
- + Previous generation DR5 agonists have been ineffective due to poor clustering or led to unintended apoptosis in normal hepatocytes likely due to unwanted hyperclustering⁷

Our Engineering Goal:



Design a DR5 agonist that can selectively induce enhanced apoptosis in tumor cells

Our Solution:

Tetravalent DR5 agonist empirically designed to simultaneously engage four DR5 molecules to drive enhanced clustering/signaling in tumor cells while minimizing off-target effects

Four DR5 sdAbs
with key immunogenic
epitopes removed


Engineered Fc
Minimize effector
function

106 kDa

**Smaller than
conventional mAb**
may allow for better
tumor penetration

Preliminary Phase 1 Data in Unresectable or Metastatic Conventional Chondrosarcoma

INBRX-109



+ Data cut point **8-Nov-2022**, study ongoing

+ Response per RECISTv1.1 per Investigator assessment, data subject to change (e.g., some data raw and not verified)

+ PR=Partial Response, SD=Stable Disease, PD=Progressive Disease

+ ▶ Patient still on treatment **IDH**- isocitrate dehydrogenase (IDH1/IDH2) mutant

+ *Off-study per subject request (e.g., resection) or **Investigator discretion

INBRX-109 Phase 2 Registration-enabling Study Design in Chondrosarcoma



Randomization

Conventional chondrosarcoma, Grades 1, 2 and 3, unresectable or metastatic

Stratification

by line of therapy, Grade and IDH1/2 mutation status

INBRX-109

 **N=134***

 **3 mg/kg every three weeks**



Ongoing

Placebo

 **N=67***

 **Until PD or toxicity with cross-over to INBRX-109**

ENDPOINTS

Primary: Progression free survival

Secondary: Overall survival, quality of life, overall response rate, duration of response, disease control rate, safety, etc.

2H 2024

- + No approved systemic therapeutic for the treatment of chondrosarcoma
- + FDA Fast Track designation and orphan-drug designation in unresectable and metastatic conventional chondrosarcoma

PFS from other placebo-controlled chondrosarcoma studies

Therapeutic	IPI-926 (HH)
Control arm	Placebo
Subject number	100 (2:1)
Placebo arm	Median PFS 2.9 months


Source~ CTOS 2013 Wagner et al.

Therapeutic	Regorafenib
Control arm	Placebo
Subject number	46 (2:1)
Placebo arm	Median PFS~ 2 months

Source~ European Journal of Cancer 2021 Florence Duffaud et al.

Many Patients with Local Disease Eventually Progress to Unresectable or Metastatic Chondrosarcoma, Providing an Annual Prevalent Patient Pool of ~2.5K in the U.S.

Conventional chondrosarcoma patient flow



KEY TAKEAWAYS

- + Unresectable or metastatic opportunity estimated at **~2.5K** patients in the U.S. today vs. reported incidence of ~1.5K given tendency for local disease to progress to unresectable or metastatic
- + Longer term growth opportunity in the peri-operative setting for high-risk patients with **~1.6K** prevalent patients in the U.S. today

INBRX-109 on the Horizon

PART 3



Combination studies



Ongoing



N=20

Pancreatic adenocarcinoma
2nd line with mFOLFIRI



N=20

Ewing sarcoma with
Irinotecan + Temozolomide



N=20

Colorectal Cancer with
FOLFIRI



N=20

SDH-deficient GIST with
Temozolomide

Data releases: 2H 2023

POTENTIAL FUTURE OPPORTUNITIES



Solid Tumors

- + IAP antagonists
- + Targeted therapies
- + Checkpoint inhibitors
- + Selective kinase inhibitors
- + Additional combo agents



Hematologic tumors

- + Bcl-2 inhibitors
- + Proteasome inhibitors
- + Additional combo agents



Additional sarcoma indications

INBRX-105

PD-L1 x 4-1BB Multispecific

INHIBR_X

Localizing and Potentiating the Anti-cancer Effects of the 4-1BB Pathway

- + 4-1BB (CD137/TNFRS9) is a member of the tumor necrosis factor (TNF) receptor superfamily and is an attractive target for immunotherapy due to its increased expression on tumor reactive TILs¹
- + Agonistic 4-1BB mAbs have shown promising anti-tumor activity in early clinical studies^{2,3}
- + However, systemic activation of 4-1BB has led to a narrow therapeutic window limited by toxicity^{2,4}


Our Engineering Goal:



Design a 4-1BB agonist with an optimized therapeutic index

Our Solution:

Tetravalent PD-L1 and 4-1BB bispecific antibody that localizes the 4-1BB costimulatory effect to a PD-L1 rich tumor microenvironment



INBRX-105 is a Potential Best-in-class 4-1BB Agonist

PD-L1 x 4-1BB Bispecifics

CANDIDATE	FORMAT	4-1BBL BLOCKING
INBRX-105	Bivalent/Bivalent	No
Gen-1046	Monovalent/Monovalent	n/a
MCLA-145	Monovalent/Monovalent	Yes
FS222	Bivalent/Bivalent	n/a
PRS-343	Bivalent/Bivalent	No
ND021	Monovalent/Monovalent	n/a

Monoclonal 4-1BB Antibodies

CANDIDATE	IGG SUBCLASS	4-1BBL BLOCKING
Urelumab	IgG4	Yes
Utomilumab	IgG2	No
CTX-471	IgG4	No
ADG106	IgG4	Yes
ATOR-1017	IgG4	Yes
AGEN2373	IgG1	No
LVGN6051	unknown	n/a


INBRX-105

INHIBRX

INBRX-105 has the Potential to be the First 4-1BB Agonist with a Robust Therapeutic Window

INBRX-105

Phase 1 Trial Design



- + Therapeutic window observed in the CPI-refractory population with responses both in single agent and in combination with Keytruda
- + Single agent complete response observed


INBRX-106

Hexavalent OX40 Agonist

INHIBR_X

INBRX-106 is a Potential Best-in-class OX40 Agonist

CANDIDATES	VALENCY	ISOTYPE	LIGAND BLOCKING
INBRX-106	Hexa-	IgG1	N
MOXR-0916	Bi-	IgG1	Y
GSK-3174998			
BMS-986178			
INCAGN-1949			
ABBV-368			
IBI-101			
MEDI-0562			
PF-04518600	Bi-	IgG2	Y
BGB-A445	Bi-	IgG1	N
BAT6026	Bi-	IgG1 afucosylated mAb	n/a



INBRX-106

Phase 1 INBRX-106 Trial as a Single Agent and in Combination with Keytruda®

INBRX-106

Single agent

PART 1



INBRX-106 single-agent dose escalation

N=20

- + 3+3 design
- + Locally advanced or metastatic solid tumors
- + All-comers



Complete

PART 2



INBRX 106 single-agent dose expansion

N=82-94

- + 0.03 mg/kg (RP2D) at 2 dosing schedules (Q3W or Q9W) in tumor types responsive to CPIs



Ongoing

NSCLC

Melanoma

HNSCC

G/GEA

RCC

1H 2024

Single agent

- + 4/10 response evaluable NSCLC & melanoma patients with duration of stable disease* greater than 6 months (three CPI-exposed patients and one CPI-naïve uveal melanoma patient)
- + Longest duration of stable disease was 2+ years (NSCLC patient refractory to Keytruda)**
- + Well-tolerated with mild or moderate immune-related toxicities

In combination

PART 3



Dose escalation with Keytruda

N=30

- + Locally advanced or metastatic solid tumors
- + mTPI design
- + >3 subjects per dose level:
 - 0.01, 0.03, 0.1 and 0.3 mg/kg (Q3W)
- + No prescreening; all-comers



Complete

PART 4



Dose expansion with Keytruda

N=170

- + Relapsed or refractory to CPI
- + PDL1 TPS ≥ 1% (NSCLC)
- + PDL1 CPS ≥ 1% (PD-L1 basket)



Ongoing

PDL1+ NSCLC r/r

PDL1+ basket

PDL1+ cutaneous melanoma

PDL1+ uveal melanoma

PDL1+ HNSCC

PDL1+ nasopharyngeal carcinoma

1H 2024

In combination

- + Durable responses with anti-PD-1 in CPI refractory patients across multiple tumor types
- + Well-tolerated with mild or moderate immune-related toxicities


CPI r/r

CPI naïve

Potential Market Opportunity for INBRX-106 and INBRX-105

PD-1/PD-L1 WW Revenue


(in \$ billions)



**Keytruda and Opdivo® go off patent in 2028*

PD-1/PD-L1 WW Revenue by Indication

(in \$ billions)



Cisleukin™ Platform

A Targeted
Cis-IL2 Platform

INHIBR_X

Targeting the Robust Anti-tumor Effects of IL-2 to Overcome Off-target Toxicity

- + IL-2 is a potent stimulator of cytotoxic cell types with natural anti-tumor activity that has shown great promise as a single agent in multiple cancers¹
- + However, efforts to mitigate the toxicities of IL-2 therapy have been at the expense of anti-tumor efficacy restricting its therapeutic window

Our Engineering Goal:


 Design a potent, targeted IL-2 able to widen the therapeutic window and minimize off-target toxicity

Our Solution:

Proprietary Cisleukin™ platform able to restrict IL-2 effects to a specific target cell/antigen utilizing high affinity sdAb and an engineered cis-binding IL-2 variant (IL2-X)

High affinity
sdAb targeting

Targeting of IL2-X via high-affinity sdAbs
allows pinpointed signaling
on defined target cell populations



Low affinity
IL2-X

Low affinity IL2-X binding of CD25 and CD122 when not
bound to a target cell/antigen that is recovered upon
binding of the sdAb

Cisleukin Platform

INBRX-121

NK Cell Targeted Cisleukin™
Molecule



INHIBR_X

An NK Cell Targeted Cisleukin™ Molecule

INBRX-121

Description/MOA


- + Natural Killer (NK) cells have potent cytolytic activity and are not limited by MHC-I presentation of tumor-associated antigens like T cells
- + NKp46 is an NK cell-specific marker that maintains expression on tumor-infiltrating NK cells
- + Targeting of affinity-reduced IL2-X via high-affinity sdAbs for NKp46 ensures specific modulation of NK cells without impacting unwanted cell populations like regulatory T cells



INBRX-121 is poised to bring NK cells to the forefront of immunotherapy

INBRX-121

Improved NK Activity



- + Expands NK cell numbers
- + Overcomes suppression
- + Enhances cytotoxic capacity



Safety with durability



- + Cytokine release syndrome not caused by NK cells
- + Extended exposure drives durability



Multiple potential paths forward



Single agent
Activated NK cells exhibit immediate cytotoxicity




Combination therapy
Enhances the activity of therapeutic antibodies


Expanded mouse NK cells and enhanced their cytotoxic potential

INBRX-121


NK cell expansion




NK cell activation



NK cell cytolytic activity



Synergized with approved therapeutic antibodies




TREATMENT	COMPLETE RESPONSES
Rituxan®	0/10
INBRX-121 + Rituxan®	9/10

INBRX-121

INBRX-121 synergized with Rituxan® in a subcutaneous Raji tumor model resulting in complete tumor regression

INBRX-121 safely expanded NK cells in non-human primates




Expanded NK cells
in a dose-dependent
manner (up to 12-fold)
that persists for more than
21 days and can be dosed
multiple times safely



Tolerated in repeat
dose range studies
up to 10 mg/kg


INBRX-121

NK cell expansion in blood after
a single dose of INBRX-121 at 1 mg/kg:



Expanded NK cells from Lymphoma patients

IL-2 signaling in patient NK cells



NK cells from Lymphoma patients expressed NKp46 at levels similar to or above that of healthy donors


- +: 1 nM INBRX-121

DLBCL: Diffuse large B-cell Lymphoma

MCL: Mantle cell Lymphoma

FL: Follicular Lymphoma

Patient NK cell proliferation




Patient NK cells responded to stimulation with INBRX-121 by upregulating pSTAT5 and showed an increased proliferative potential

INBRX-121

INHIBRX

Expanded the number of NK cells while enhancing their individual cytotoxic capacities



Raji cell killing after INBRX-121 pre-incubation

INBRX-121

INBRX-121 increased NK cell-mediated killing of Raji cells in the presence of a Rituximab sequence analog (Anti-hCD20-hIgG1).

11025 N. Torrey Pines Rd
Ste 200
La Jolla, CA 92037
www.inhibrx.com

Investor Relations:
Kelly Deck, CFO
Kelly@inhibrx.com

INHIBRX

